Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials-Reference-Cited by-同舟云学术

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials

Published:2016-02-23 Issue:3 Volume:68 Page:299-307
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Combe Bernard¹,Furst Daniel E.²,Keystone Edward C.³,van der Heijde Désirée⁴,Luijtens Kristel⁵,Ionescu Lucian⁵,Goel Niti⁶,Emery Paul⁷

Affiliation:

1. Lapeyronie University Hospital, Montpellier I University Hospital Montpellier France

2. University of California Los Angeles

3. University of Toronto Toronto Ontario Canada

4. Leiden University Medical Center Leiden The Netherlands

5. UCB Pharma Brussels Belgium

6. UCB Pharma Smyrna Georgia

7. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals National Health Service Trust Leeds UK

Funder

UCB Pharma

Publisher

Wiley

Subject

Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr.22676

Reference30 articles.

1. An update on methotrexate

2. A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis

3. Methotrexate in rheumatoid arthritis;Swierkot J;Pharmacol Rep,2006

4. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature

5. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis;Pincus T;Clin Exp Rheumatol,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study;Modern Rheumatology;2024-03-29

2. An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs;Rheumatology;2019-10-18

3. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data;Modern Rheumatology;2019-01-11

4. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients;Modern Rheumatology;2018-07-23

5. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group;Clinical Rheumatology;2016-10-12